Muzastotug is under clinical development by Adagene Suzhou and currently in Phase II for Hepatocellular Carcinoma.

BGB-10188 is under clinical development by BeiGene and currently in Phase II for Renal Cell Carcinoma. According to GlobalData, Phase II drugs for Renal Cell Carcinoma have a 29% phase transition ...

Announcing a new publication for Acta Materia Medica journal. Fatty acid (FA) reprogramming has a significant role in liver cancer. However, the contribution of FA metabolism reprogramming to the ...

Transarterial chemoembolization (TACE) improves survival in cirrhotic patients with hepatocellular carcinoma (HCC). The optimal schedule, best anticancer agent and best technique are still unclear.

Background: Hepatoblastoma (HBL) and hepatocellular carcinoma (HCC) are respectively the first and the second most common pediatric malignant liver tumors. The purpose of this study was to ...

The following is a summary of “Alpha-fetoprotein combined with initial tumor shape irregularity in predicting the survival of ...

There’s a stigma surrounding liver cancer. Once you tell people you’ve got it, often you sense a slight judgment. “Oh”, you ...

Alcohol, commonly found in beverages, medicines, and even household products, is classified as a known human carcinogen by ...

North Carolina construction worker Derek Barnett, 55, lost more than 70 pounds on a unique nutrition and fitness journey ...

This study evaluated the impact of obesity and diabetes mellitus on HCC recurrence and survival after hepatic resection, ...

Can-Fite’s data will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium Can-Fite enrolls patients for its ...

The Barbara Ann Karmanos Cancer Institute in Detroit says the new TheraBionic P1 device, an FDA-approved, at-home treatment, ...